Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DNMT1

Gene summary for DNMT1

Gene summary.

Gene information	Species	Human
	Gene symbol	DNMT1
	Gene ID	1786
	Gene name	DNA methyltransferase 1
	Gene Alias	ADCADN
	Cytomap	19p13.2
	Gene Type	protein-coding
	GO ID	GO:0000122
	UniProtAcc	I6L9H2

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1786	DNMT1	AEH-subject3	Human	Endometrium	AEH	1.24e-02	1.57e-01	-0.2576
1786	DNMT1	AEH-subject4	Human	Endometrium	AEH	2.96e-05	2.44e-01	-0.2657
1786	DNMT1	EEC-subject3	Human	Endometrium	EEC	6.70e-05	-1.33e-01	-0.2525
1786	DNMT1	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	9.46e-17	-1.07e-01	-0.1869
1786	DNMT1	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	1.96e-16	-1.32e-01	-0.1875
1786	DNMT1	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	2.20e-20	-1.76e-02	-0.1883
1786	DNMT1	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	6.54e-13	1.18e-01	-0.1934
1786	DNMT1	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	4.64e-22	-1.22e-01	-0.1917
1786	DNMT1	GSM6177622_NYU_UCEC3_lib2_lib2	Human	Endometrium	EEC	2.11e-24	-1.51e-01	-0.1916
1786	DNMT1	LZE2T	Human	Esophagus	ESCC	2.24e-07	7.95e-01	0.082
1786	DNMT1	LZE4T	Human	Esophagus	ESCC	1.57e-16	4.21e-01	0.0811
1786	DNMT1	LZE5T	Human	Esophagus	ESCC	2.17e-03	9.04e-01	0.0514
1786	DNMT1	LZE7T	Human	Esophagus	ESCC	2.40e-30	1.75e+00	0.0667
1786	DNMT1	LZE8T	Human	Esophagus	ESCC	3.87e-04	3.06e-01	0.067
1786	DNMT1	LZE20T	Human	Esophagus	ESCC	7.93e-07	1.26e-01	0.0662
1786	DNMT1	LZE22D1	Human	Esophagus	HGIN	8.03e-06	1.95e-01	0.0595
1786	DNMT1	LZE22T	Human	Esophagus	ESCC	2.70e-05	5.47e-01	0.068
1786	DNMT1	LZE24T	Human	Esophagus	ESCC	1.06e-13	3.60e-01	0.0596
1786	DNMT1	LZE22D3	Human	Esophagus	HGIN	1.74e-03	5.91e-01	0.0653
1786	DNMT1	LZE21T	Human	Esophagus	ESCC	2.46e-08	5.61e-01	0.0655

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00486604	Endometrium	AEH	regulation of smooth muscle cell proliferation	43/2100	180/18723	1.09e-06	3.68e-05	43
GO:200125210	Endometrium	AEH	positive regulation of chromosome organization	25/2100	82/18723	1.95e-06	5.93e-05	25
GO:00486594	Endometrium	AEH	smooth muscle cell proliferation	43/2100	184/18723	2.04e-06	6.14e-05	43
GO:00330022	Endometrium	AEH	muscle cell proliferation	51/2100	248/18723	1.26e-05	2.77e-04	51
GO:00072657	Endometrium	AEH	Ras protein signal transduction	63/2100	337/18723	3.09e-05	5.66e-04	63
GO:00426925	Endometrium	AEH	muscle cell differentiation	68/2100	384/18723	8.88e-05	1.30e-03	68
GO:00330446	Endometrium	AEH	regulation of chromosome organization	36/2100	187/18723	8.27e-04	7.73e-03	36
GO:00011017	Endometrium	AEH	response to acid chemical	28/2100	135/18723	9.24e-04	8.43e-03	28
GO:00486613	Endometrium	AEH	positive regulation of smooth muscle cell proliferation	23/2100	104/18723	1.03e-03	9.15e-03	23
GO:00432005	Endometrium	AEH	response to amino acid	24/2100	116/18723	2.14e-03	1.65e-02	24
GO:00063258	Endometrium	AEH	chromatin organization	64/2100	409/18723	3.69e-03	2.52e-02	64
GO:00712302	Endometrium	AEH	cellular response to amino acid stimulus	16/2100	71/18723	4.68e-03	2.99e-02	16
GO:1904705	Endometrium	AEH	regulation of vascular associated smooth muscle cell proliferation	19/2100	90/18723	4.69e-03	2.99e-02	19
GO:1990874	Endometrium	AEH	vascular associated smooth muscle cell proliferation	19/2100	91/18723	5.32e-03	3.32e-02	19
GO:1904707	Endometrium	AEH	positive regulation of vascular associated smooth muscle cell proliferation	12/2100	49/18723	6.75e-03	3.94e-02	12
GO:00712293	Endometrium	AEH	cellular response to acid chemical	17/2100	80/18723	6.76e-03	3.94e-02	17
GO:0031453	Endometrium	AEH	positive regulation of heterochromatin assembly	5/2100	12/18723	7.10e-03	4.09e-02	5
GO:0120263	Endometrium	AEH	positive regulation of heterochromatin organization	5/2100	12/18723	7.10e-03	4.09e-02	5
GO:0051148	Endometrium	AEH	negative regulation of muscle cell differentiation	15/2100	68/18723	7.45e-03	4.23e-02	15
GO:200125213	Endometrium	EEC	positive regulation of chromosome organization	26/2168	82/18723	9.70e-07	3.31e-05	26

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa002704	Endometrium	EEC	Cysteine and methionine metabolism	15/1237	52/8465	6.02e-03	3.12e-02	2.33e-02	15
hsa0027011	Endometrium	EEC	Cysteine and methionine metabolism	15/1237	52/8465	6.02e-03	3.12e-02	2.33e-02	15
hsa002702	Liver	HCC	Cysteine and methionine metabolism	35/4020	52/8465	3.03e-03	9.94e-03	5.53e-03	35
hsa002703	Liver	HCC	Cysteine and methionine metabolism	35/4020	52/8465	3.03e-03	9.94e-03	5.53e-03	35

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DNMT1

SNV

Missense_Mutation

c.461C>T

p.Pro154Leu

p.P154L

P26358

protein_coding

tolerated_low_confidence(0.06)

benign(0)

TCGA-AN-A0FS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DNMT1

SNV

Missense_Mutation

c.2366N>T

p.Pro789Leu

p.P789L

P26358

protein_coding

deleterious(0.03)

possibly_damaging(0.778)

TCGA-AR-A251-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

DNMT1

SNV

Missense_Mutation

c.4084G>C

p.Asp1362His

p.D1362H

P26358

protein_coding

deleterious(0)

probably_damaging(0.987)

TCGA-BH-A0GY-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cyotxan

DNMT1

SNV

Missense_Mutation

c.3744G>T

p.Met1248Ile

p.M1248I

P26358

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-BH-A0GY-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cyotxan

DNMT1

SNV

Missense_Mutation

c.2401N>A

p.Asp801Asn

p.D801N

P26358

protein_coding

tolerated(0.17)

benign(0.131)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DNMT1

SNV

Missense_Mutation

novel

c.3280N>T

p.Gly1094Cys

p.G1094C

P26358

protein_coding

deleterious(0)

probably_damaging(0.967)

TCGA-C8-A3M8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

DNMT1

SNV

Missense_Mutation

novel

c.4388N>T

p.Ser1463Leu

p.S1463L

P26358

protein_coding

deleterious(0.01)

possibly_damaging(0.662)

TCGA-C8-A8HQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DNMT1

SNV

Missense_Mutation

c.2980N>C

p.Asp994His

p.D994H

P26358

protein_coding

deleterious(0)

probably_damaging(0.982)

TCGA-E2-A1B6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Adriamycin

DNMT1

SNV

Missense_Mutation

rs749258509

c.2623N>A

p.Asp875Asn

p.D875N

P26358

protein_coding

tolerated(0.12)

benign(0.043)

TCGA-EW-A1PA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

DNMT1

insertion

Nonsense_Mutation

novel

c.1100_1101insGTGGAGGGCTGGGCGCGGTGGCTCATGCCTGTAATCCTAGCACTTT

p.Lys368TrpfsTer11

p.K368Wfs*11

P26358

protein_coding

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		Guadecitabine	GUADECITABINE
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		DEMETHOXYCURCUMIN	DEMETHOXYCURCUMIN	19112019
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		5-FLUORODEOXYURIDINE	FLOXURIDINE	15899874
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		IFOSFAMIDE	IFOSFAMIDE
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		TETRAHYDROCURCUMIN	TETRAHYDROCURCUMIN	19112019
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		PMID27376512-Compound-PG-11048
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		DNDI1417346	CHEMBL1490332
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		S-110
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		ARSENIC TRIOXIDE		16613325
1786	DNMT1	DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE		PMID27376512-Compound-CROs

Page: 1 2 3 4 5 6 7